

asx announcement

MESOBLAST CLEAR TO PROCEED WITH ANGIOBLAST ACQUISITION

Melbourne, Australia; 19 November 2010: Australian regenerative medicine company, Mesoblast Limited (ASX:MSB; ADR:MBLTY), today announced that the required period for any anti-trust objection under the United States Hart-Scott-Rodino (HSR) anti-trust improvement Act 1976 in respect of its acquisition of Angioblast Systems Inc. has expired.

On completion of the acquisition, the enlarged Mesoblast Group will have on issue approximately 250 million shares and at today's share price, a market capitalization approaching \$750 million.

Under the HSR Act, given the size of the transaction, both entities involved in the merger, acquisition, or consolidation were required to file notifications to the United States anti-trust authorities and to observe the statutory waiting period before consummating the transaction.

The parties are now able to proceed with finalization of all merger conditions.

About Mesoblast Limited

Mesoblast Limited (ASX:MSB; ADR:MBLTY) is a world leader in commercialising biologic products for the broad field of regenerative medicine. Mesoblast has the worldwide exclusive rights for a series of patents and technologies developed over more than 10 years relating to the identification, extraction, culture and uses of adult Mesenchymal Precursor Cells (MPCs). www.mesoblast.com

For further information, please contact:

Julie Meldrum
Corporate Communications Director
T: + 61 (03) 9639 6036
E: julie.meldrum@mesoblast.com